Abbott’s Xience Stent Drives 35% Growth In Overseas Vascular Sales
This article was originally published in The Gray Sheet
Executive Summary
Abbott continues to look forward to U.S. approval of its Xience V everolimus-eluting coronary stent by the end of June as European adoption of the device drives growth in its vascular unit
You may also be interested in...
Abbott Reports Xience Stent Launch Off To A Good Start
Abbott says sales of its Xience V everolimus-eluting coronary stent during its first two weeks on the U.S. market have exceeded the company's pre-launch projections
Abbott Reports Xience Stent Launch Off To A Good Start
Abbott says sales of its Xience V everolimus-eluting coronary stent during its first two weeks on the U.S. market have exceeded the company's pre-launch projections
Xience V / Promus Drug-Eluting Stent Is Off And Running On U.S. Market
Abbott remains confident that it will gain 25% to 30% share of the U.S. drug-eluting stent market over the next year now that it has launched its Xience V everolimus-eluting stent